Port-a-Cath® extravasation of vesicant cytotoxics: Surgical options for a rare complication of cancer chemotherapy
Introduction
Due to therapeutic advances over the last decade, long-term survival of cancer patients has increasingly been observed,1, 2, 3 and systemic chemotherapy is a cornerstone in the treatment of solid tumours. However, problems associated with the administration of cytotoxic chemotherapy via peripheral veins has led to increased use of implanted central venous access devices such as Port-a-Cath®.4, 5 Although the use of a totally implanted venous access port system (TIVAP) was initially considered safe, subsequent studies have reported that extravasations from a port have occurred in 0.3%–4.7% of cases.6 In addition, management of central port extravasation is poorly defined. To the best of our knowledge, no relevant series of patients has been published that has addressed the management of port extravasations with vesicant compounds into the subcutaneous space. Correspondingly, due to the insufficient knowledge available in this field and the lack of clinical evidence, there are no standard procedures to adhere to Ref. 7.
Detection of an extravasation event is also hampered by delayed local swelling.8, 9 Compared with peripheral extravasations, loose subcutaneous tissue in the infraclavicular region is combined with reduced pain sensitivity. As a consequence, the amount of extravasated cytotoxic agent is potentially greater and possibly associated with more severe and prolonged sequelae in comparison with peripheral extravasation events.10, 11, 12
In the present study, eight patients with port extravasation into the subcutaneous space were assessed. These patients either underwent explantation of the central venous device and a subcutaneous Wash-Out Procedure (SWOP) immediately after detection, or the patients experienced a delay in detection and this was followed by removal of the port, débridement, and flap coverage when necessary.
Section snippets
Patients and methods
Data obtained from patients receiving anticancer therapy that was administered via a TIVAP (Port-a-Cath®) between 2006 and 2014 were analysed. During this period, a total of 4101 TIVAPs had been implanted at our institution. Of these cases, eight patients experienced extravasation of a vesicant or highly cytotoxic compound. Due to the tissue damage that was caused by the extravasation, surgical intervention was necessary for all of these patients. Four women and four men with a mean age of 53
Patient management
In three out of eight patients, extravasation was detected during the infusion of cytotoxic agents. Explantation of the TIVAP in combination with the SWOP was performed for two of these patients on the same day the extravasation was detected, or two days thereafter for another patient. A total of 2000 ml saline solution (0.9%) was used to rinse the tissue surrounding the TIVAP for each patient. Due to the delayed detection of extravasation in the remaining five patients, the SWOP was not
Discussion
For this small series of patients, a standard procedure for the surgical management of highly toxic extravasation events was applied to patients receiving antineoplastic therapy via TIVAP. To our knowledge, this represents the largest series of homogenously treated patients with port extravasation events to date (Fig. 4). Previously, investigations of port complications have focused on general events including damage to neighbouring organs, the pneumothorax, port infections and sepsis,
Acknowledgements
The authors would like to thank Zeljka Stojanovic for her commitment and analysis of epirubicin concentrations in the collected fluids.
References (23)
Extravasation injuries
Br J Plast Surg
(1993)- et al.
Subcutaneous wash-out procedure (SWOP) for the treatment of chemotherapeutic extravasations
J Plast Reconstr Aesthetic Surg JPRAS
(2011) - et al.
Extravasation of systemic hemato-oncological therapies
Ann Oncol Off J Eur Soc Med Oncol ESMO
(2004) - et al.
Totally implantable venous-access ports: local problems and extravasation injury
Lancet Oncol
(2002) - et al.
Management of chemotherapy extravasation: ESMO-EONS clinical practice guidelines
Ann Oncol Off J Eur Soc Med Oncol ESMO
(2012) - et al.
Long-term survival of a patient with invasive signet-ring cell carcinoma of the urinary bladder managed by combined s-1 and Cisplatin adjuvant chemotherapy
Case Rep Urol
(2013) - et al.
Presentation of a patient with pT2bN1M0 small cell carcinoma of the uterine cervix who obtained long-term survival with maintenance chemotherapy, and literature-based discussion
Eur J Gynaecol Oncol
(2011) - et al.
Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy
Med Oncol
(2011) - et al.
Port-A-Cath: a study of complication rates
S D J Med
(1991) - et al.
Comparison of a totally implantable access device for chemotherapy (Port-A-Cath) and long-term percutaneous catheterization (Broviac)
South Med J
(1988)
Chemotherapy extravasation from implanted ports
Oncol Nurs Forum
Cited by (22)
Vascular access device type for systemic anti-cancer therapies in cancer patients: A scoping review
2024, Critical Reviews in Oncology/HematologyEfficacy, Safety, and Cost-Effectiveness of Intracavitary Electrocardiography-Guided Catheter Tip Placement for Totally Implantable Venous Access Port
2022, Annals of Vascular SurgeryCitation Excerpt :In addition, the multivariate analysis showed that BMI was an independent risk factor for TIVAP-related complications (OR = 1.334, 95% CI: 1.139 - 1.563, P < 0.001). Being overweight or obese can substantially increase the thickness of the subcutaneous fatty layer covering the TIVAPs, thereby impairing correct localization and puncture of the port system.24 In addition, obesity was also associated with extravasation24 and catheter-related infection.25-26
Muscle sparing latissimus dorsi flap for reconstruction of a large chemo-necrosis of the chest wall: A case report
2022, Annales de Chirurgie Plastique EsthetiqueCitation Excerpt :The site of extravasation should then be closely monitored at least at 24 hours, 1 week, 2 week and then as necessary considering the local evolution. When the tissue damage is too important, surgery is needed [3] to resect the necrotic tissues and, in most severe cases a reconstruction with a flap may be necessary [4]. We present the case of a 71-year-old patient with a large necrosis of the chest wall after extravasation of epirubicin (a vesicant agent) from an implanted port-a-cath.
Extravasation of Epirubicin chemotherapy from a port-a-cath causing extensive breast necrosis: Sequential imaging findings and management of a breast cancer patient
2021, Radiology Case ReportsCitation Excerpt :Central venous access is used for administration of chemotherapy as it minimizes its toxic effects of extravasation [5]. Extravasation injury is rarer with central administration than peripheral routes [6] however, central venous devices such as Port-a-Cath have shown extravasation rates of up to 6% in the literature [4,7]. There have been several reports of extravasation with the use of central venous access devices with rates from 0.26% to 4.7% [8,9].
A Comparison Between Upper Arm and Chest for Optimal Site of Totally Implanted Venous Access Ports in Patients with Female Breast Cancer
2018, Annals of Vascular SurgeryCitation Excerpt :In multivariate analysis using the Cox regression model, we found that higher BMI was an independent risk factor for catheter-related infections. This might be because the depth of the subcutaneous fatty layer makes it more difficult to inject the needle through the port chamber, thereby increasing the number of needle sticks required and the risk of extravasation of cytotoxic drugs.27 Injuries to adjacent organs, such as the pneumothorax and hemothorax as well as nerve palsy, can occur due to inadvertent puncture when using the Seldinger technique.28
Surgical management after Oxaliplatin extravasation: A case report and literature review
2023, Journal of Vascular Access